Clinlab Navigator

MESOMARK

Malignant mesothelioma is a rare but highly aggressive neoplasm with poor prognosis. Epidemiologic studies have established exposure to asbestos fibers as the primary cause of malignant mesothelioma.

As of May 2022, MESOMARK® (Fujirebio Diagnostics) was the only FDA approved blood-based biomarker test for mesothelioma. It is an enzyme-linked immunosorbent assay (ELISA) for the quantitative measurement of soluble mesothelin-related peptides (SMRPs), which are released into the bloodstream by mesothelioma cells.

MESOMARK results alone are not sufficient to diagnose mesothelioma. The MESOMARK label states the test can help monitor patients with epithelioid mesothelioma and biphasic mesothelioma but not sarcomatoid mesothelioma.

Reference interval is 0.0 – 1.5 nmol/L. Patients with mesothelioma have higher SMRP levels than healthy patients. 

Specimen requirement is q serum separator tube or plain red top tube of blood. MESOMARK is available at ARUP Laboratories. 

References

Beyer, H. et al. MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma. Clinical Chemistry, 2007;53:666-672.

Schneider J, et al. Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer, J Thorac Oncol. 2008; 3:1317–1324.

Updated Articles

Herpes Simplex Virus…

Humans are the only natural reservoir of herpes simplex virus (HSV) type 1 (HSV-1) and type 2 (HSV-2). HSV is one of the most prevalent viral infections in the world. Genital herpes is a sexually transmitted disease caused by either HSV-1 or HSV-2.…

New Articles

VEXAS Syndrome

VEXAS syndrome is a rare disease that causes late onset recurrent episodes of inflammation and hematologic abnormalities in men over the age of 50. Clinical manifestations of VEXAS syndrome are variable and include skin lesions, recurrent fever,…

Blog

Laboratory Tests for…

Cirrhosis is defined as the fibrotic replacement of liver tissue that can result from any chronic liver disease. Cirrhosis affects approximately 2.2 million adults in the United States and is associated with mortality rates of 21.9 per 100 000…